Takeda Pharmaceutical Company Limited (TAK) News
Filter TAK News Items
TAK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TAK News Highlights
- TAK's 30 day story count now stands at 13.
- Over the past 24 days, the trend for TAK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about TAK are TSE, RARE and PBYI.
Latest TAK News From Around the Web
Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived TherapiesOSAKA, Japan, & GENEVA, Switzerland, September 29, 2022--As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s experti |
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?TAK vs. ZTS: Which Stock Is the Better Value Option? |
Puma Biotech (PBYI) Inks Agreement for Takeda's AlisertibPuma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib. |
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung CancerPuma Biotechnology Inc (NASDAQ: PBYI) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK) to license the worldwide research and development and commercial rights to alisertib for cancer indications. Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia. Under the terms of the agreement, Puma will assume sole responsibility for the global develo |
Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infectionTakeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has authorized (Notice of Compliance) LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 Compared to conventionally used antivirals to treat post-transplant CMV, LIVTENCITY offers twice the efficacy1 and more than 10 times less toxicity.1* |
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United StatesOSAKA, Japan & CAMBRIDGE, Mass., September 19, 2022--Takeda (TSE:4502/NYSE:TAK) and Enel North America today announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power grid from a 79 megawatt (MW) portion of Enel’s Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy LLC, advances progress towards achieving Takeda’s goals of reducing 40 percent of scopes 1 and 2 greenhouse gas (GHG) emi |
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior TherapiesOSAKA, Japan & CAMBRIDGE, Mass., September 16, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem c |
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in YearsWhen dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world. |
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's DiseaseTakeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease |